TNDM Stock Forecast & Price Target

Tandem Diabetes Care is attractive fundamentally because it is executing through a healthy underlying demand backdrop, with record Q2 shipments of 22K pumps, new starts up 20%+ sequentially, and MDI conversions representing roughly 70% of new pump starts, while Type 2 indicators remain positive. Its PayGo pharmacy shift is improving economics rather than weakening them, with 10% of U.S. sales already through pharmacy, formulary coverage at 45%, and supply ASPs above the $350/month assumption, helping offset near-term upfront pump revenue pressure and supporting higher lifetime value. The pipeline also adds durability to growth, as Mobi accounts for more than half of new customer shipments, Mobi Tubeless is slated for a 2H'26 launch, and Control-IQ plus the Sigi patch pump expand the company’s innovation runway in a large underpenetrated market.

Tandem Diabetes Care is facing a fundamentally fragile setup because its growth thesis depends heavily on Mobi gaining traction in the U.S. and internationally, while competitive entries and new products could limit share gains in a rapidly changing insulin pump market. The company’s concentration in insulin delivery systems, exposure to reimbursement changes, dependence on third-party suppliers, and risk of recalls or supply disruptions all heighten execution risk, especially if customer retention weakens or pharmacy-channel conversion fails. With roughly three-quarters of revenue from the U.S. and an EV-to-Sales framework using ~0.75x 2027E sales implying limited downside support, slower product adoption, unsuccessful R&D, and the possibility that GLP-1s reduce demand justify the negative outlook.